{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:14:52Z","timestamp":1756995292655,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Hemolytic uremic syndrome (HUS) is rare in neonates. It is probably an under-recognized condition in the early postnatal period as it presents similarly to the most common perinatal asphyxia and to differentiate the two conditions is challenging. We describe the clinical presentation of a potential new subtype of neonatal HUS triggered by hypoxic-ischemic event. Our patient was successfully treated by a single dose of Eculizumab as early as at 9 days of life.<\/jats:p><jats:p><jats:bold>Case Report:<\/jats:bold> A 35-weeks infant was born with low hemoglobin and subsequently developed respiratory distress, hypotension, and acidosis. Blood transfusion was administered, acidosis corrected, neurological examination remained reassuring. Few hours later he developed renal failure, macroscopic hematuria, hemobilia, thrombocytopenia and coagulopathy refractory to platelet and fresh frozen plasma transfusions. No infection was found. Haptoglobin was non-measurable, and schistocytes present, complement factors C3, C4 and B were low, FBb increased. HUS was suspected. A single dose of Eculizumab\u2122 was administered on day 9 of life. No genetic mutation of atypical HUS was found. He was discharged with improving renal function and developing cholestasis.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In neonates with hemolytic anemia, thrombocytopenia, hematuria and renal failure, HUS should be suspected. In neonatal HUS Eculizumab should be considered as first-line therapy and discontinuation can be considered if no genetic mutation is found and clinical condition improves. In very young patients, cholestasis could appear as potential side effect of Eculizumab\u2122.<\/jats:p>","DOI":"10.3389\/fped.2020.579607","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T06:00:57Z","timestamp":1613628057000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab"],"prefix":"10.3389","volume":"8","author":[{"given":"Dorottya","family":"Kelen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetta","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Godart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Adams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Stordeur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Ismaili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1007\/s00467-007-0570-7","article-title":"Perinatal asphyxia may present with features of neonatal atypical hemolytic uremic syndrome","volume":"12","author":"Biran","year":"2007","journal-title":"Pediatr Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1007\/s00467-005-1871-3","article-title":"Neonatal hemolytic uremic syndrome after mother-to-child transmission of Escherichia coli O157","volume":"20","author":"Ulinski","year":"2005","journal-title":"Pediatr Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2431-8-17","article-title":"Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy. A randomised controlled trial","volume":"8","author":"Azzopardi","year":"2008","journal-title":"BMC Pediatr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.arcped.2015.11.020","article-title":"Successful treatment of neonatal atypical haemolytic uremic syndrome with C5 monoclonal antibody","volume":"23","author":"Anastaze Stelle","year":"2016","journal-title":"Arch P\u00e9diatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00467-012-2296-4","article-title":"Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab","volume":"28","author":"Besbas","year":"2013","journal-title":"Pediatr Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1182\/blood-2013-12-547067","article-title":"Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP","volume":"123","author":"Cataland","year":"2014","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/sji.12154","article-title":"Complement profile in neonates of different gestational ages","volume":"79","author":"Grumach","year":"2014","journal-title":"Scand J Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1046\/j.1365-3083.2003.01326.x","article-title":"Ontogeny of complement regulatory proteins - concentrations of factor H, factor I, c4b-binding protein, properdin and vitronectin in healthy children of different ages and in adults","volume":"58","author":"De Paula","year":"2003","journal-title":"Scand J Immunol."},{"volume-title":"Soliris (eculizumab) Full Prescribing Information","year":"2011","key":"B9"},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5414\/CN108532","article-title":"Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab","volume":"84","author":"Sharma","year":"2015","journal-title":"Philadelphia Clin Nephrol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1007\/s00467-014-2933-1","article-title":"Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency","volume":"29","author":"Michaux","year":"2014","journal-title":"Pediatr Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00467-019-04234-6","article-title":"Escherichia coli-associated haemolytic uremic syndrome and severe chronic hepatocellular cholestasis: complication or side effect of eculizumab?","volume":"34","author":"Mauras","year":"2019","journal-title":"Pediatr Nephrol."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.579607\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T06:00:59Z","timestamp":1613628059000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.579607\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":13,"alternative-id":["10.3389\/fped.2020.579607"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.579607","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"article-number":"579607"}}